RGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue GrowthPositive revenue growth indicates renewed demand for Repligen’s bioprocessing products. Because its consumables support ongoing biologic manufacturing runs, sustained customer production and capacity expansion could support durable top-line growth.
Cash GenerationStrong, growing operating and free cash flow provides internal funding for research, capacity, integration, and debt obligations. This resilience is especially valuable because cash generation has held up better than reported earnings during periods of profitability volatility.
Cell Therapy ExpansionThe proposed BioLife combination broadens Repligen beyond traditional biologics into cell therapy, adding differentiated media and processing tools. The expanded platform could improve long-term growth and profitability if the transaction closes and targeted synergies are achieved.
Bears Say
Uneven Revenue And MarginsThe recovery is not yet a return to prior consistency. Uneven revenue and lower margins suggest exposure to customer inventory, facility investment, and bioprocessing cycles, which may limit the durability of earnings improvement over the next several quarters.
Low Returns On EquityLow returns on equity indicate that Repligen is currently converting its asset and equity base into bottom-line profit inefficiently. Unless profitability improves materially, this can constrain retained-value creation and reduce the effectiveness of future capital deployment.
Debt And Acquisition ExecutionAlthough leverage remains manageable, higher debt reduces financial flexibility as Repligen pursues a sizable acquisition. The expected growth and synergy benefits also depend on approvals, closing, and successful integration, creating execution risk over the medium term.
Repligen News
RGN FAQ
What was Repligen Corp’s price range in the past 12 months?
Currently, no data Available
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is CHF7.75B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Nov 03, 2026 which is in 58 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Jul 28, 2026. The company reported CHF0.437 earnings per share for the quarter, beating the consensus estimate of CHF0.362 by CHF0.075.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.37.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,435,620 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of CHF0.437 in its last earnings report, beating expectations of CHF0.362. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in CH:RGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF146.02 (― Upside)
CHF146.02 (― Upside)
Blogger Sentiment
Bullish
CH:RGN Sentiment 60%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Repligen Corp
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGN Company Deck
RGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.View all CH:RGN earnings summariesRGN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGN Stock 12 Month Forecast
Average Price Target
―West Pharmaceutical Services
―
BioLife Solutions
―
Avantor
―
Stevanato Group
―
Solventum Corporation
―